• Discovery

    Proprietary technologies used by our team include B cell Select, phage display, and single-step hybridoma cloning with semi-solid media and clone picking.
  • Alternative Species & Strains

    We have broad experience with transgenic animals, knock-out strains, and a variety of species including, but not limited to, chickens, rabbits, camelids, and more.
  • Targets

    Any target class including GPCRs, ion channels, phosphopeptides, small molecules, secreted proteins, etc. Antibodies generated for numerous applications, including therapeutic, immuno-onocology, CAR-T, and more.
  • Connect with Scientists

    Request a free target analysis with our experts.

ImmunoPrecise Featured Services

With over 25 years of experience in the custom antibody business, ImmunoPrecise provides high satisfaction through a customized professional approach.
B cell Select
B cell Select mAb Discovery

ImmunoPrecise is excited to offer custom B cell Select Antibody Discovery. This proprietary technology allows for selection of target specific B cells from any tissue in a variety of animal species.

Learn More: B cell Select

Phage Display
Phage Display

Our phage display approach is based on building custom immune libraries from multiple species, or the selection of antigen specific recombinant antibody fragments from our proprietary human or llama phage libraries.

Learn More: Phage Display

Hybridoma Development
Hybridoma Development

Coupled with advanced hybridoma technologies, Rapid Prime is ImmunoPrecise’s proprietary immunization protocol, which saves months in development time in combination with our Single-Step semi-solid media selection and clone picking. Positive hybridoma clones are identified just 32 days from project initiation.

Learn More: Hybridoma Development

Rabbit Monoclonals
Rabbit Monoclonals

ImmunoPrecise’s proprietary rabbit monoclonal development allows for the screening of the immune repertoire of the rabbit, creating the power to select the desired antibody directly from the B cells using our B cell Select antibody discovery platform.

Learn More: Rabbit mAbs

Antibody Optimization
Antibody Optimization

At ImmunoPrecise, we offer the following antibody optimization services: antibody chimerization, antibody humanization, and antibody affinity maturation.

Learn More: Antibody Optimization

Antibody Manufacturing
Antibody Manufacturing

Our proprietary expression technology is designed to deliver fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications.

Learn More: Antibody Manufacturing

Start Your Project

We are ready to initiate the immunization phase of your custom antibody development project immediately.


ImmunoPrecise Conference and Tradeshows
  • ImmunoPrecise Attending & Exhibiting at Antibody Engineering & Therapeutics Europe 2019

    The ImmunoPrecise Antibodies team will be exhibiting at Antibody Engineering & Therapeutics (AET) Europe 2019 in Amsterdam, NL from June 11th-13th, 2019. AET Europe is the industry’s European meeting for Antibody and Protein Therapeutic Science, Technology and Networking. This year’s conference will have a strong focus on “drug development” and will feature preclinical and clinical case

  • ImmunoPrecise Attending & Exhibiting at #PEGS 19 in Boston, April 8-11

    The 2019 Protein Engineering Summit (PEGS) in Boston is the industry’s preeminent event that inspires innovative biotherapeutic protein drug development. Plan to meet the IPA team at our booth (#622) to find out how to accelerate therapeutic antibody discovery utilizing advanced, innovative technologies yielding greater candidate diversity than traditional methods. Or, schedule a meeting to discuss

  • Meet Us at European Antibody Therapeutics Xchange

    ImmunoPrecise to Lead Scientific Round-table Discussion and Poster Session at hubXchange’s European Antibody Therapeutics event. At hubXchange’s European Antibody Therapeutics event, held in Munich on March 21st, Dr. Debby Kruijsen will lead a round-table discussion entitled “Implementing discovery strategies to value the therapeutic potential of lead antibody candidates” while Nienke Smits will present a poster entitled